August 5, 2025

Instylla Appoints Sean Boyle as Chief Executive Officer

August 5, 2025—Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolization, announced the appointment of Sean Boyle as Chief Executive Officer. Boyle will replace Amar Sawhney as CEO. Sawhney will continue as Chairman of the Board of the company.

According to the company, Boyle brings 15 years of leadership in the medical device industry with experience in diverse business units. Before joining Instylla, Boyle served as Vice President and General Manager of Peripheral Intervention at Becton Dickinson, where he oversaw a global portfolio of approximately $1 billion in revenue.

Instylla, which was founded in 2017 by Incept LLC, stated that it is developing resorbable embolic agents to advance interventional radiology, with initial clinical applications in interventional oncology and control of hemorrhage in the peripheral vasculature.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

August 5, 2025

Instylla Appoints Sean Boyle as Chief Executive Officer

Current Issue

Keep In Touch